Chemotherapy

Pre-clinicalRecruiting

0 views this week 0 watching💤 Quiet

Interest: 23/100

23

Hype Score

Development Stage

1

Pre-clinical

2

Phase 1

3

Phase 2

4

Phase 3

5

Approved

Indication / Disease

Barrett's Esophagus

Conditions

Barrett's Esophagus, Esophageal Cancer

Trial Timeline

Jan 1, 2015 → Jan 1, 2027

NCT ID

About Chemotherapy

Chemotherapy is a pre-clinical stage product being developed by Pacific Biosciences for Barrett's Esophagus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02634645. Target conditions include Barrett's Esophagus, Esophageal Cancer.

What happened to similar drugs?

3 of 3 similar drugs in Barrett's Esophagus were approved

Approved (3) Terminated (0) Active (0)

✅Esomeprazole + Aspirin + RofecoxibAstraZenecaApproved

✅Esomeprazole + LansoprazoleAstraZenecaApproved

✅Esomeprazole MagnesiumAstraZenecaApproved

Hype Score Breakdown

Clinical

3

Activity

15

Company

5

Novelty

0

Community

0

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05704621	Phase 2	Recruiting	Dec 1, 2023	Dec 28, 2028	Ovarian Cancer
NCT02634645	Pre-clinical	Recruiting	Jan 1, 2015	Jan 1, 2027	Barrett's Esophagus

Competing Products

3 competing products in Barrett's Esophagus

See all competitors

Product	Company	Stage	Hype Score
Esomeprazole + Aspirin + Rofecoxib	AstraZeneca	Approved	43
Esomeprazole + Lansoprazole	AstraZeneca	Approved	43
Esomeprazole Magnesium	AstraZeneca	Approved	43